Back to Treatments

Treatment

Durvalumab + Gemcitabine/Cisplatin

1
Conditions
5
Trials
10K
Participants
28%
Average Safety

Condition Evidence

Gallbladder and biliary tract cancer

5 trials · 10K participants

60% effectiveness · 28% safety
Durvalumab + Gemcitabine/Cisplatin | DFDA